You are here

COGNOSCI INC

Company Information
Address
2 DAVIS DR
RESEARCH TRIANGLE PARK, NC 27709-0000
United States



Information

UEI: NZW4KLUZ17G3

# of Employees: 4


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Neurorestorative Strategy for Chemotherapy-induced Peripheral Neuropathy

    Amount: $326,711.00

    DESCRIPTION (provided by applicant): Chemotherapy-induced peripheral neuropathy (CIPN) is a major dose-limiting side effect of many commonly used chemotherapeutic agents, including platinum drugs and ...

    SBIRPhase I2009Department of Health and Human Services National Institutes of Health
  2. Novel Screen for Targeted CLL Therapeutics

    Amount: $289,114.00

    DESCRIPTION (provided by applicant): Of the nearly 84,000 cases of leukemia in the Western world, B-cell chronic lymphocytic leukemia (B-CLL) is the most common and accounts for approximately 30% of a ...

    SBIRPhase I2009Department of Health and Human Services National Institutes of Health
  3. Neuroprotective Apolipoprotein-E Analogs Continuation

    Amount: $2,609,100.00

    DESCRIPTION (provided by applicant): Traumatic brain injury (TBI), principally as a result of impaction on the intact closed skull, occurs in vehicular incidents, falls, acts of violence, and sports ...

    SBIRPhase II2008Department of Health and Human Services National Institutes of Health
  4. Novel Therapeutic for SAH

    Amount: $249,686.00

    DESCRIPTION: Subarachnoid Hemorrhage (SAH) is a form of stroke that occurs in nearly 40,000 patients each year in the United States. Despite advances in early diagnosis and management, SAH remains a f ...

    SBIRPhase I2008Department of Health and Human Services National Institutes of Health
  5. Novel Targeted Therapy for CLL

    Amount: $257,133.00

    DESCRIPTION (provided by applicant): Of the nearly 84,000 cases of leukemia in the Western world, B-cell chronic lymphocytic leukemia (B-CLL) is the most common and accounts for approximately 30% of a ...

    SBIRPhase I2008Department of Health and Human Services National Institutes of Health
  6. Novel Intervention for Amyloid-Induced Neuroinflammation

    Amount: $263,420.00

    DESCRIPTION (provided by applicant): Novel Intervention for Amyloid-Induced Neuroinflammation Extracellular deposition of the amyloid a-protein (Aa) in brain is a prominent pathological feature of Alz ...

    STTRPhase I2007Department of Health and Human Services National Institutes of Health
  7. Novel Intervention for Colitis

    Amount: $279,250.00

    DESCRIPTION (provided by applicant): Novel Intervention for Colitis The scope of the current proposal is to determine whether administration of an apoE mimetic peptide, COG112, improves clinical, hist ...

    STTRPhase I2007Department of Health and Human Services National Institutes of Health
  8. Novel Treatment for Parkinson's Disease

    Amount: $290,289.00

    DESCRIPTION (provided by applicant): Parkinson's Disease (PD) is a devastating neurodegenerative disorder that affects approximately 500,000 people in the US and an additional 50,000 are diagnosed eac ...

    SBIRPhase I2007Department of Health and Human Services National Institutes of Health
  9. Novel Therapy for Sepsis

    Amount: $231,235.00

    DESCRIPTION (provided by applicant): Sepsis remains an important medical problem that results in over 200,000 deaths each year in the United States. Sepsis syndrome results in multisystem organ failur ...

    SBIRPhase I2007Department of Health and Human Services National Institutes of Health
  10. Development of Remyelinating Agents

    Amount: $286,509.00

    DESCRIPTION (provided by applicant): Multiple sclerosis (MS) is one of the devastating neurological diseases in young adults that is pathologically characterized by inflammation and demyelination in t ...

    SBIRPhase I2007Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government